| Clinical data | |
|---|---|
| Other names | LU-38012; LU38012 |
| Drug class | Dopamine D4 receptor antagonist |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C19H20ClN3 |
| Molar mass | 325.84 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Lu 38-012 is a potent and selective dopamine D4 receptor antagonist which has been used in scientific research. It has an affinity (Ki) for the dopamine D4.2 receptor of 7.5 nM and showed 16-fold selectivity for this receptor over the dopamine D2S receptor (Ki = 120 nM). The drug had relatively little affinity for other dopamine receptors. Affinities at other targets have also been reported. The drug produces hypolocomotion and reverses dextroamphetamine- and phencyclidine (PCP)-induced hyperlocomotion without producing catalepsy in rodents. Lu 38-012 partially substituted for clozapine in drug discrimination tests in rodents. It was developed by Lundbeck and was first described in the scientific literature by 2006.